NCT06282588 2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
Clinical Trials
22 trialsNCT06330805 2026-03-09
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05827081 2026-03-02
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT07158021 2026-02-13
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06397703 2026-01-28
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
Phase 2 Recruiting
NCT05498272 2026-01-23
NePtune
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05050084 2026-01-14
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT02960022 2025-12-17
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT04569747 2025-11-13
ADEPT
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06348264 2025-09-23
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Peking University First Hospital
Phase 2 Recruiting
NCT06922318 2025-09-17
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06512207 2025-09-09
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University
Phase NA Recruiting
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT05765500 2025-08-11
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05169112 2025-03-20
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute
Phase 3 Recruiting